GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novaccess Global Inc (OTCPK:XSNX) » Definitions » Cyclically Adjusted Price-to-FCF

Novaccess Global (Novaccess Global) Cyclically Adjusted Price-to-FCF : (As of Jun. 19, 2024)


View and export this data going back to . Start your Free Trial

What is Novaccess Global Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Novaccess Global Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Novaccess Global's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novaccess Global Cyclically Adjusted Price-to-FCF Chart

Novaccess Global Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Novaccess Global Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Novaccess Global's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Novaccess Global's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novaccess Global's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Novaccess Global's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Novaccess Global's Cyclically Adjusted Price-to-FCF falls into.



Novaccess Global Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Novaccess Global's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Novaccess Global's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.002/131.7762*131.7762
=-0.002

Current CPI (Mar. 2024) = 131.7762.

Novaccess Global Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -0.247 100.560 -0.324
201409 -0.010 100.428 -0.013
201412 -0.050 99.070 -0.067
201503 -0.238 99.621 -0.315
201506 -0.068 100.684 -0.089
201509 0.033 100.392 0.043
201512 -0.065 99.792 -0.086
201603 -0.023 100.470 -0.030
201606 -0.108 101.688 -0.140
201609 -0.036 101.861 -0.047
201612 0.130 101.863 0.168
201703 -0.050 102.862 -0.064
201706 -0.012 103.349 -0.015
201709 -0.078 104.136 -0.099
201712 -0.043 104.011 -0.054
201803 -0.032 105.290 -0.040
201806 0.028 106.317 0.035
201809 -0.047 106.507 -0.058
201812 0.008 105.998 0.010
201903 -0.006 107.251 -0.007
201906 0.022 108.070 0.027
201909 -0.032 108.329 -0.039
201912 0.130 108.420 0.158
202003 -0.016 108.902 -0.019
202006 -0.030 108.767 -0.036
202009 -0.015 109.815 -0.018
202012 -0.013 109.897 -0.016
202103 -0.013 111.754 -0.015
202106 -0.010 114.631 -0.011
202109 -0.019 115.734 -0.022
202112 -0.013 117.630 -0.015
202203 -0.016 121.301 -0.017
202206 -0.015 125.017 -0.016
202209 -0.011 125.227 -0.012
202212 -0.008 125.222 -0.008
202303 -0.004 127.348 -0.004
202306 -0.005 128.729 -0.005
202309 -0.007 129.860 -0.007
202312 0.000 129.419 0.000
202403 -0.002 131.776 -0.002

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Novaccess Global  (OTCPK:XSNX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Novaccess Global Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Novaccess Global's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Novaccess Global (Novaccess Global) Business Description

Industry
Traded in Other Exchanges
N/A
Address
8485 E,Washington Street, No. 127, Chagrin Falls, OH, USA, 44023
Novaccess Global Inc is a biopharmaceutical company that is developing novel immunotherapies to treat brain tumor patients in the United States. The company's team of experts is working to strengthen the capability of the human body's defense against cancer.
Executives
Jason Michael Anderson director 8584 E. WASHINGTON STREET, NO. 127, CHAGRIN FALLS OH 44023
John Cassarini director 880 WINTER STREET, BUILDING 4, WALTHAM MA 02451
Neil J Laird officer: Chief Financial Officer
Larry Michael Yukich officer: Chief Financial Officer 8834 MAYFIELD ROAD, SUITE C, CHESTERLAND OH 44026
Dwain Morris-irvin officer: Chief Executive Officer 8834 MAYFIELD ROAD, SUITE C, CHESTERLAND OH 44026
Innovest Global, Inc. 10 percent owner 8834 MAYFIELD ROAD, CHESTERLAND OH 44026
Daniel G. Martin director, 10 percent owner, officer: Chief Executive Officer 8834 MAYFIELD RD, CHESTERLAND OH 44026
Michael A Russak director
Osmund Mark Fundingsland director 1237 LAS PALMAS DR, SANTA BARBARA CA 93110
Thomas A Anderson director 2116 PASEO PRIMERO, SANTA FE NM 87501
Jeff J Huitt officer: CFO 10651 WEST 34TH PLACE, WHEAT RIDGE CO 80033
Joseph Grimes officer: COO 6 CLEOME, LADERA RANCH CA 92694
Tom M Djokovich director, 10 percent owner, officer: President 23332 VISTA CARILLO, LAGUNA NIGUEL CA 92677
Brian Altounian director, officer: Secretary 626 N. DOHENY DRIVE, WEST HOLLYWOOD CA 90069
Thomas Djokovich director, officer: President 1601 CLOVERFIELD BLVD, 2ND FL. S. TOWER, SANTA MONICA CA 90404